All In Biotech

Drug Trial Radar · NCT07897734

TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients

A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 (RAS Inhibitor) in Patients With MTAP-null Pancreatic Cancer and MTAP-null Non-Small Cell Lung Cancer With RAS Mutation

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

188

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Nov 2031

Study completion May 2032

Sponsor

Lead sponsor
Tango Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Erasca, Inc.
First posted
Oct 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TNG462-C103 is a Phase 1/2 study to investigate the safety and antitumor activity of vopimetostat (TNG462) combined with ERAS-0015 in patients with MTAP-null pancreatic or MTAP-null non-small cell lung cancer with RAS mutation.

Conditions

  • PDAC
  • PDAC - Pancreatic Ductal Adenocarcinoma
  • NSCLC
  • RAS Mutation
  • MTAP Deletion
  • Lung Cancer
  • Pancreatic Cancer Metastatic
  • Thoracic Cancer

Interventions

  • vopimetostatDrug

    MTA-cooperative PRMT5 inhibitor

  • ERAS-0015Drug

    Pan-RAS molecular glue

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 Maximum Tolerated DoseTime frame: 21 days
  2. Phase 2 Combination Anti-neoplastic ActivityTime frame: 12 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.